Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends
Decentralize, Diversify And Prioritize The Patient
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
You may also be interested in...
BioAsia 2023: Focus Research Outside US, Take ‘One Health’ Approach To Prevent Next Pandemic
Speakers from BMS, Takeda, UNICEF and more discussed how a shift in R&D focus, free flow of data on animal and human health, public sector investment and higher regulatory flexibility are key to make ‘One Health’ work and prevent future pandemics
Experts Want To Drop Confusing Terminology For Decentralized Clinical Trials
A new scientific paper drawn up by experts on behalf of the EU public-private Trials@Home project discusses the pros and cons of various terms being used to refer to decentralized clinical trials and suggests a unified way forward.
EU Issues More Q&As To Support Compliance With Clinical Trials Regulation
The European Commission has come up with a workaround to address a current lack of functionality in the Clinical Trial Information System, while the European Medicines Agency has addressed technical queries on CTIS and the Clinical Trials Regulation.